GLP-1 Pipeline Update: August 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior, Pipeline DISCLAIMER The drug pipeline is fluid
Moreover, HMGB1 serves as an indispensable intermediate bridge in HSPA12As protection against liver IRI
Neurodevelopment in children with intrauterine growth restriction: adverse effects and interventions
These may include but are not limited to: Pain or swelling at the injection site Allergic reactions (extremely rare) If you experience any concerning side effects, contact your healthcare provider immediately
This stomach disorder represents a gastrointestinal condition where the stomach requires an unusually extended period to discharge its contents